Accuray announced that the company has a 510(k) pending for an online adaptive therapy option, Cenos, for its Radixact System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO Annual Meeting in San Diego, California, October 1-4, 2023. Cenos is designed to enable medical care teams to quickly and efficiently make adjustments, if necessary, to a treatment plan while the patient is still on the treatment table.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARAY:
